SUMMARY

This summary aims to give you an overview of the information contained in this document. As this is a summary, it does not contain all the information that may be important to you, and is qualified in its entirety by and should be read in conjunction with, the full text of this document. You should read the whole document before you decide to [REDACTED] in the [REDACTED].

There are risks associated with any investment. Some of the particular risks associated with [REDACTED] in the [REDACTED] are set out in "Risk Factors." You should read that section carefully before you decide to [REDACTED] in the [REDACTED].

In particular, we are a biotechnology company seeking to [REDACTED] on the Main Board of the Stock Exchange under Chapter 18A of the Listing Rules as we do not meet the requirements under Rules 8.05(1), (2) or (3) of the Listing Rules. There are unique challenges, risks and uncertainties associated with [REDACTED] in companies like ours. In addition, we have designated WH007, WH006 and WH002 as our Core Products to satisfy the eligibility requirements under Chapter 18A of the Listing Rules and Chapter 2.3 of the Guide for New Listing Applicants. We may continue to incur substantial costs and expenses in relation to the R&D activities for the Core Products, and our Core Products may not be successfully developed or marketed. Your [REDACTED] decision should be made in light of these considerations.

OVERVIEW

We are a biopharmaceutical company focused on innovation in natural medicines ("**Natural Medicine(s)**") since our inception in 2010, with capabilities spanning discovery, development, industrialization and commercialization of high-barrier, innovative therapies. In parallel, we develop drug delivery system ("**DDS**") to address technical bottlenecks of in vivo drug delivery. As of the Latest Practicable Date, we have established a product pipeline comprising (i) one commercialized product, *Sangbo'en*, for type 2 diabetes, (ii) three Core Products, including WH007 for polycystic ovary syndrome ("**PCOS**"), WH006 for obesity, and WH002 for neoadjuvant treatment for breast cancer, and (iii) five other drug candidates.

Natural Medicines refer to naturally derived medicinal substances and their formulations developed under Modern Medical Theories. Under China's drug registration classification framework, Natural Medicines are registered by reference to the TCM classification pathway. See "Regulatory Overview — Laws and Regulations relating to our Business — Regulations on Drug Administration — NDA, Approval and Renewal."

THERE IS NO ASSURANCE THAT WE WILL ULTIMATELY BE ABLE TO DEVELOP AND MARKET OUR CORE PRODUCTS OR ANY OF OUR PIPELINE PRODUCTS SUCCESSFULLY.

The following chart sets forth the development status of our product pipeline as of the Latest Practicable Date:

Pipeline	Innovation Type	Indication	Pre-clinical Research / IND / Phase I / Phase II / Phase III / NDA	Commercial Right[1]	Next Milestone
WH001 *Sangbo'en*	Molecular entity-Natural Medicine	Type 2 diabetes	[2] NMPA	Global	N/A[3]
WH007 ★	Molecular entity-Natural Medicine	PCOS	NMPA	Global	Phase II clinical trial to be initiated in 2026
WH006 ★	Molecular entity-Natural Medicine	Obesity	NMPA	Global	Phase II clinical trial to be completed in 2027
WH002 ★	DDS	Neoadjuvant treatment for breast cancer	[4] NMPA	Global	Phase III clinical trial to be initiated in 2026
WH008	Molecular entity-Natural Medicine	MASH		Global	IND filing to the NMPA
WH004	DDS	Hypertension	NMPA	Global	IND approval expected to be obtained in H1 2026
WH010	DDS	Gastric cancer	NMPA	Global	Phase II clinical trial to be initiated
WH003	Molecular entity-Natural Medicine	Inflammatory and immune		Global	IND filing to the NMPA
WH009	Molecular entity-DDS	Stroke and dementia		Global	IND filing to the NMPA

Commercialized product ★ Core products Other drug candidates

Abbreviations: IND: investigational new drug; NDA: new drug application; NMPA: National Medical Products Administration; PCOS: polycystic ovary syndrome; DDS: drug delivery system; MASH: metabolic dysfunction-associated steatohepatitis.

Notes:

(1) We maintain the exclusive global rights to develop, manufacture and commercialize our commercialized product, Core Products and other drug candidates.

(2) We have been assigned the exclusive patent rights, as well as the subsequent rights to develop, manufacture, and commercialize WH001 from the Institute of Materia Medica, Chinese Academy of Medical Sciences (中國醫學科學院藥物研究所) (the "**IMM**"). At the time of such assignment, WH001 was still in Phase I clinical trial stage.

(3) WH001 *Sangbo'en* has been commercialized in 2020.

(4) We have been assigned the exclusive patent rights, as well as the subsequent rights to develop, manufacture, and commercialize WH002 from the IMM. At the time of such assignment, WH002 was still in preclinical research stage.

SUMMARY

BUSINESS MODEL

Our innovation is built upon the integrated R&D capability covering discovery and industrialization of Natural Medicines and DDS. We independently develop our Core Products WH007 and WH006. WH002 was assigned to us by the IMM as well as the subsequent rights to develop, manufacture, and commercialize WH002. At the time of such assignment, WH002 was still in preclinical research stage. For further details of the assignment arrangements, please see "Business — Collaboration Arrangement."

Complementing our R&D activities, we have built industrialization and manufacturing capabilities to support scale-up and commercialization. We have established good manufacturing practices ("**GMP**")-standard commercial-scale in-house manufacturing facilities. We believe that our in-house manufacturing capability enhances the efficiency of our development and manufacturing processes, allowing us to achieve reliable quality and cost control, and ensure stable and timely supply of clinical trial sample and commercial drug to weather any supply chain disruptions. In addition, we have established an in-house sales and marketing team which engages in the promotion of our products through various marketing activities and sales channels. Leveraging existing experience for commercialized product, we believe our in-house commercial capabilities will provide strong support for the upcoming commercialization and marketing of our drug candidates.

OUR COMMERCIALIZED PRODUCT AND CORE PRODUCTS

Our Commercialized Product *Sangbo'en*

Sangbo'en is a Natural Medicine (currently classified as Traditional Chinese Medicine ("**TCM**") Category 1.2) indicated for the treatment of type 2 diabetes. In addition to potent glucose lowering effects, it exhibits multiple pharmacological effects that support more extensive metabolic management in diabetic patients. According to CIC, as of the Latest Practicable Date, *Sangbo'en* is the first and only original Natural Medicine in China approved for glycemic control, and also the world's first plant-derived Natural Medicine based on clearly defined active components for glycemic control. *Sangbo'en* is developed using Mulberry Twig (SangZhi) Alkaloid ("**SZ-A**") derived from mulberry twigs as active pharmaceutical ingredients ("**API(s)**"). SZ-A is a group of active components with well-defined material basis, stable and controllable quality, and clear mechanism of action ("**MOA**").

Sangbo'en obtained new drug application ("**NDA**") approval from the National Medical Products Administration of China ("**NMPA**") in March 2020, and was included in the National Reimbursement Drug List ("**NRDL**") in the same year.

Our Core Product WH007

WH007 is a Natural Medicine candidate (classified as TCM Category 2.3) using SZ-A as the API and is intended for PCOS. According to CIC, the prevalence of PCOS among women of reproductive age in China is estimated to be approximately 7.8%, translating into 34.4 million patients in 2024, and this number is projected to reach 37.6 million by 2032, representing a CAGR of 1.1%. Current clinical management primarily focuses on symptomatic treatment but does not address the underlying pathophysiology of PCOS. According to CIC, as of the Latest Practicable Date, no pharmacological therapies have been approved globally with a specific indication for PCOS.

SUMMARY

WH007 targets core pathophysiological mechanisms through the regulation of hypothalamic — pituitary — ovarian axis ("**HPO axis**") of PCOS. Preclinical studies have shown that WH007 significantly improves estrous cycles, polycystic ovary morphology, and metabolic abnormalities, regulates hormone levels, and significantly restores fertility. In IIT, WH007 has been shown to significantly improve the menstrual cycle and free androgen index ("**FAI**") in patients. In addition, WH007 presents favorable safety profile with no reproductive toxicity.

WH007 obtained the investigational new drug ("**IND**") approval from the NMPA in December 2025 to conduct Phase II clinical trial.

Our Core Product WH006

WH006 is a Natural Medicine candidate (classified as TCM Category 2.3) using SZ-A as the API and is intended for obesity. According to CIC, the prevalence of obesity among Chinese adults has been steadily rising, with approximately 277.4 million obese patients in 2024, and this number is projected to reach 330.3 million by 2032, representing a CAGR of 2.2%. Preclinical studies have shown that WH006 promotes lipid metabolism, reduces lipid synthesis, helps control the preference for high-fat foods, reduces body fat while preserving muscle mass, increases bone mineral density, and offers a good safety profile along with convenient administration.

WH006 obtained the IND approval from the NMPA in November 2023, with its Phase I clinical trial initiated in May 2024 and completed in November 2024. In August 2025, we completed Phase II clinical trial registration and disclosure on the Center for Drug Evaluation ("**CDE**") registration platform, and initiated Phase II clinical trial.

Our Core Product WH002

WH002 is a paclitaxel-cholesterol conjugated tumor-targeting lipid emulsion (classified as Chemical Drug Category 2.2). WH002 was formulated based on a lipid nano-carrier technology built on cholesterol-based supramolecular complexes. We focus WH002 on neoadjuvant treatment for Luminal subtype breast cancer. According to CIC, in 2024, there were approximately 2.4 million newly diagnosed cases of breast cancer worldwide. Human epidermal growth factor receptor 2 ("**HER2**")-negative breast cancer accounted for approximately 77.0%–80.0% of all cases, of which around 80.0% were hormone receptor ("**HR**")-positive (HR + /HER2-, the "**Luminal subtype**") Luminal subtype. WH002 has favorable tumor tissue accumulation, penetration and tumor cell targeting, accompanied by lower systemic toxicity, an increased tolerated dose and improved anti-tumor activity.

WH002 obtained the IND approval from the NMPA in April 2019, with its Phase I clinical trial initiated in April 2022 and completed in December 2023, and its Phase II clinical trial initiated in June 2024 and completed in November 2025. We intend to initiate the Phase III clinical trial in 2026.

OUR STRENGTHS

We attribute our success to and distinguish ourselves by the following key competitive strengths of (i) our pioneering Natural Medicine *Sangbo'en* and Core Products for metabolic diseases through indication expansion; (ii) our anti-tumor candidate demonstrates improvements of safety, efficacy and convenience; (iii) platform capabilities enabling end-to-end development of Natural Medicines and DDS; (iv) academically driven commercialization supported by a nationwide distribution network; and (v) experienced senior management and industry-leading R&D capabilities. See "Business — Our Strengths."

SUMMARY

OUR STRATEGIES

We will continue to expand our business following the strategies of (i) advancing clinical development of our pipeline products; (ii) expanding overseas commercialization and international clinical registration; (iii) enhancing production capacity and efficiency; (iv) executing a targeted commercialization strategy; and (v) strengthening our interdisciplinary R&D and commercialization talent pipeline. See "Business — Our Strategies."

RESEARCH AND DEVELOPMENT

We consistently devote resources to research and development to pave for long-term growth. In 2024 and the nine months ended September 30, 2024 and 2025, our research and development costs were RMB58.0 million, RMB38.3 million and RMB41.5 million, respectively. Our research and development costs attributable to our Core Products were RMB35.6 million, RMB23.1 million and RMB26.4 million in 2024 and the nine months ended September 30, 2024 and 2025, respectively, representing 61.3%, 60.5% and 63.7% of our total research and development costs for the same period, respectively.

We have built an R&D team with deep expertise and extensive experience across Natural Medicines and multi-indication expansion, DDS development and translation, and clinical research and development. As of September 30, 2025, we have established a dedicated R&D team of 89 members. 46 members of our R&D team held master's or above degrees, including eight members with doctorate degrees. Our R&D team is led by Dr. LIU Zhihua, our deputy general manager, dean of the Institute for Pharmaceutical Innovation and senior director of the New Drug R&D Center of the Institute for Pharmaceutical Innovation. Dr. LIU Zhihua has both theoretical and practical expertise in innovative drug discovery and development, clinical positioning, risk assessment, regulatory application and commercialization, and is capable of formulating forward-looking intellectual property strategies. Building on our highly independent R&D efforts, our R&D activities also benefit from technical advice and scientific communication with external experts and research institutions. See "Business — Research and Development."

INTELLECTUAL PROPERTY

As of the Latest Practicable Date, we had in China 278 registered trademarks and in other jurisdictions two registered trademarks and nine domain names, which we consider to be material to our business. As of the Latest Practicable Date, we held (i) 78 issued patents, including 38 issued patents in China, and 40 registered patents in other jurisdictions, and (ii) 92 patent applications, including 30 patent applications in China, and 62 patent applications in other jurisdictions. As of the Latest Practicable Date, for our Core Products, we held (i) 37 issued patents, including 16 issued patents in China, and 21 registered patent in other jurisdictions, and (ii) 42 patent applications, including eight patent applications in China, and 34 patent applications in other jurisdictions. See "Business — Intellectual Property" for details.

COMMERCIALIZATION

We sell *Sangbo'en* to distributors, who are our direct customers and are responsible for distributing our products to hospitals, pharmacies and e-commerce platforms in China. Our in-house sales and marketing team is primarily responsible for the promotion of our products through various marketing activities and sales through different channels in China. See "Business — Marketing, Sales and Commercialization" for details.

MANUFACTURING

As of the Latest Practicable Date, we operated three manufacturing facilities, including (i) Guangxi SZ-A API production line, responsible for the production of SZ-A API, (ii) Beijing SZ-A tablets production line, responsible for the production of *Sangbo'en* for commercial sale as well as WH007 and WH006 samples for clinical trial, and (iii) Beijing paclitaxel tumor-targeting lipid emulsion production line, responsible for the production of WH002 samples for clinical trial. See "Business — Manufacturing" for details.

OUR CUSTOMERS AND SUPPLIERS

All of our customers are distributors of *Sangbo'en*. In 2024 and the nine months ended September 30, 2025, our revenue generated from our five largest customers amounted to RMB179.3 million and RMB168.1 million, respectively, accounting for 86.2%, and 81.0% of our total revenue in the respective period, respectively, and revenue generated from our largest customer alone accounted for 43.9%, and 42.3% of our total revenue in the respective period, respectively. See "Business — Our Customers" for details.

During the Track Record Period, our suppliers primarily consisted of suppliers of raw materials. In 2024 and the nine months ended September 30, 2025, our purchases from our five largest suppliers amounted to RMB30.8 million and RMB32.9 million, respectively, accounting for 18.1%, and 25.2% of our total purchases in the respective period, respectively, and purchases from our largest supplier alone accounted for 5.4%, and 8.2% of our total purchases in the respective period, respectively. See "Business — Our Suppliers" for details.

RISK FACTORS

We believe there are certain risks and uncertainties involved in our operations, some of which are beyond our control. These risks are set out in the section headed "Risk Factors" in this document. Some of the major risks we face include (i) if we are unable to successfully complete clinical development, obtain regulatory approvals or achieve commercialization for our drug candidates, or if we experience significant delays or cost overruns in doing any of the foregoing, our business and prospects could be materially and adversely affected; (ii) clinical development involves a lengthy and costly process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future trial results; (iii) we may allocate our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable or for which there is a greater likelihood of success; (iv) if we encounter delays or difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed; and (v) our drug candidates may cause undesirable adverse events ("**AE(s)**") or adverse drug reactions ("**ADR(s)**"). See "Risk Factors" for details.

SUMMARY OF HISTORICAL FINANCIAL INFORMATION

The summary of consolidated financial information should be read together with the consolidated financial information to the Accountants' Report in Appendix I to this document, including the accompanying notes and the information set out in "Financial Information" in this document.

Summary of Historical Results of Operations

The table below sets forth a summary of our results of operations in absolute amount and as percentages of our total revenue for the periods indicated.

	Year ended December 31,		Nine months ended September 30,			
	2024		2024		2025	
	RMB'000	*(%)*	*RMB'000*	*(%)*	*RMB'000*	*(%)*
			(Unaudited)		*(Unaudited)*	
Revenue	**207,953**	**100.0**	**162,075**	**100.0**	**207,333**	**100.0**
Cost of sales	(57,969)	(27.9)	(45,659)	(28.2)	(53,667)	(25.9)
Gross profit	**149,984**	**72.1**	**116,416**	**71.8**	**153,666**	**74.1**
Loss before tax	**(108,946)**	**(52.4)**	**(66,865)**	**(41.3)**	**(45,391)**	**(21.9)**
Loss and total comprehensive loss for the year/period	**(109,518)**	**(52.7)**	**(67,426)**	**(41.6)**	**(45,717)**	**(22.1)**

See "Financial information — Review of Historical Results of Operations" for details.

Non-IFRS measures

The following table reconciles adjusted net loss (non-IFRS measure) and adjusted net EBITDA (non-IFRS measure) for the periods indicated:

	Year ended December 31,	Nine months ended September 30,	
	2024	2024	2025
	RMB'000	*RMB'000*	*RMB'000*
Loss for the year/period	**(109,518)**	**(67,426)**	**(45,717)**
Add:			
Share-based payment expenses	20,708	16,985	6,508
[REDACTED]	—	—	[REDACTED]
Adjusted net loss (non-IFRS measure)	**(88,810)**	**(50,441)**	**(36,854)**
Add:			
Income tax expenses	572	561	326
Interest costs	10,540	8,074	6,220
Depreciation	22,989	17,392	16,433
Amortization	11,943	8,952	8,900
Less:			
Interest income	1,602	1,296	1,276
Adjusted EBITDA (non-IFRS measure)	**(44,368)**	**(16,758)**	**(6,251)**

SUMMARY

Summary of Selected Items of Financial Positions

The following table sets forth selected information from our combined statements of financial position as of the dates indicated.

	As of December 31, 2024	As of September 30, 2025
	RMB'000	*RMB'000 (Unaudited)*
Total current assets	279,640	342,695
Total non-current assets	398,737	389,816
Total assets	**678,377**	**732,511**
Total current liabilities	243,836	235,494
Total non-current liabilities	149,862	120,947
Total liabilities	**393,698**	**356,441**
Net Assets	**284,679**	**376,070**

See "Financial Information — Selected Balance Sheet Items" for details.

Summary of Combined Cash Flows Statements

The following table sets forth selected cash flow statement information for the periods indicated.

	Year ended December 31,	Nine months ended September 30,	
	2024	2024	2025
	RMB'000	*RMB'000 (Unaudited)*	*RMB'000 (Unaudited)*
Net cash flow used in operating activities	(87,057)	(64,924)	(22,531)
Net cash flow used in investing activities	(101,454)	(29,990)	(9,725)
Net cash flow from/(used in) financing activities	155,910	(2,734)	83,064
Net (decrease)/increase in cash and cash equivalents	**(32,601)**	**(97,648)**	**50,808**
Cash and cash equivalents at the beginning of the year/period	144,048	144,048	111,447
Cash and cash equivalents at end of year/period	**111,447**	**46,400**	**162,255**

See "Financial Information — Liquidity and Capital Resources — Cash Flows Analysis."

Our cash burn rate refers to the average monthly amount of net cash used in operating activities, capital expenditure and lease payments. We estimate that we will receive net [REDACTED] of approximately HK$[REDACTED] million in the [REDACTED], based on an [REDACTED] of HK$[REDACTED] per [REDACTED], being the low-end of the indicative [REDACTED]. Assuming an average cash burn rate going forward of 1.0 time the level in the nine months ended September 30, 2025, which is HK$[REDACTED] per month, we estimate that (i) our cash and cash equivalents on hand as of September 30, 2025 will be able to maintain our financial viability for 38 months from September 30, 2025, (ii) or if we take into account all

estimated net [REDACTED] from the [REDACTED], [REDACTED]. We will continue to monitor our cash flows from operations closely and expect to raise our next round of financing at least 12 months after the completion of the [REDACTED].

KEY FINANCIAL RATIOS

The following table sets forth our key financial ratios as of the dates or for the periods indicated.

	As of or for the year ended December 31, 2024	As of or for the nine months ended September 30, 2025
Gross profit margin[(1)] (%)	72.1	74.1
Asset-liability ratio[(2)] (%)	58.0	48.7

Notes:

(1) Gross profit margin equals gross profit divided by revenue and multiplied by 100%.

(2) Asset-liability ratio was calculated dividing total liabilities by total assets as of the dates indicated and multiplied by 100%.

PRE-[REDACTED] INVESTMENTS

Throughout the development of our Group, we received several rounds of Pre-[REDACTED] Investments in a total amount of approximately RMB1.1 billion. The valuation of our Company upon completion of the last round of the Pre-[REDACTED] Investments is approximately RMB4,038.0 million. Our broad and diverse base of Pre-[REDACTED] Investors includes Sophisticated Investors, such as dedicated healthcare funds and biotech funds as well as investment funds, namely, Beijing Pharmaceutical Fund, Langsheng Investors and Longpan Investors, each of whom has made meaningful investment in our Company at least six months before the [REDACTED], holding approximately [REDACTED]%, [REDACTED]% and [REDACTED]% of the total issued Shares respectively, immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised). For details, please refer to "History, Development and Corporate Structure — Pre-[REDACTED] Investments" in this document.

OUR CONTROLLING SHAREHOLDERS

As of the Latest Practicable Date, Mr. HUANG Yuesheng, Mr. HU Dingfei and Mr. YU Xiecai were directly interested in and entitled to exercise approximately 16.09%, 8.34% and 8.12%, respectively, of the voting right at our general meetings. As detailed in "History, Development and Corporate Structure — Acting in Concert" in this document, in December 2018, Mr. HUANG Yuesheng, Mr. YU Xiecai and Mr. HU Dingfei entered into an acting-in-concert agreement, pursuant to which, Mr. HUANG Yuesheng, Mr. HU Dingfei and Mr. YU Xiecai were and will be deemed as a group of Shareholders acting in concert as of the Latest Practicable Date and after completion of the [REDACTED]. Mr. HUANG Yuesheng acts as the general partner of Wehand Tongyuan No.1, Wehand Tongyuan No.2, Wehand Tongyuan No.3, Jiujiang Ruida and Jiujiang Ruihe, and is accordingly entitled to exercise the respective voting rights attached to the Shares held by them, which represents 1.57%, 1.57%, 0.78%, 3.92% and 15.28% of the voting rights at our general meetings as of the Latest Practicable Date, respectively. Therefore, as of the Latest Practicable Date, Mr. HUANG

Yuesheng, Mr. HU Dingfei, Mr. YU Xiecai, Wehand Tongyuan No.1, Wehand Tongyuan No.2, Wehand Tongyuan No.3, Jiujiang Ruida and Jiujiang Ruihe, directly and indirectly, were interested in and entitled to exercise a total of approximately 55.67% of the voting right at our general meetings.

Accordingly, immediately following completion of the [REDACTED], each of Mr. HUANG Yuesheng, Mr. HU Dingfei, Mr. YU Xiecai, Wehand Tongyuan No.1, Wehand Tongyuan No.2, Wehand Tongyuan No.3, Jiujiang Ruida and Jiujiang Ruihe will together constitute a group of our Controlling Shareholders under the Listing Rules and will be entitled to exercise approximately [REDACTED]% of the voting power at our general meetings (assuming the [REDACTED] is not exercised). For details, please refer to "Relationship with Our Controlling Shareholders" in this document.

LEGAL PROCEEDINGS AND NON-COMPLIANCE

We may, from time to time, become a party to various legal, arbitral or administrative proceedings arising in the ordinary course of our business. During the Track Record Period and up to the Latest Practicable Date, we had not been and were not a party to any material legal, arbitral or administrative proceedings, and we were not aware of any pending or threatened legal, arbitral or administrative proceedings against us or our Directors that could, individually or in the aggregate, have a material adverse effect on our business, financial condition and results of operations. See "Business — Legal Proceedings and Non-Compliance" for details.

[REDACTED]

DIVIDENDS

We did not declare or pay any dividend during the Track Record Period and up to the date of this document. We do not currently have a formal dividend policy or a fixed dividend payout ratio. We currently intend to retain all available funds and earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. [REDACTED] should not purchase our ordinary shares with the expectation of receiving cash dividends. Any future distribution of dividends will be subject to approval by our shareholders' meeting and may be based on our future operations and earnings,

capital requirements and surplus, general financial condition, contractual restrictions and other factors that our Directors may deem relevant as appropriate. Regulations in the PRC currently permit payment of dividends of a PRC company only out of accumulated distributable after-tax profits less any recovery of accumulated losses and appropriations to statutory and other reserves that we are required to make, as determined in accordance with its articles of association and the accounting standards and regulations in China. As advised by our PRC Legal Adviser, taking into account the aforesaid, we may not have sufficient or any distributable profits to make dividend distributions to our Shareholders in a given year, in view of our accumulated losses, or even if we become profitable, as we will only be able to declare or pay dividends out of our distributable profits until (i) the accumulated losses are covered by our after-tax profits, and (ii) sufficient statutory and other reserves are drawn in accordance with the relevant laws, regulations and our constitutional documents. In light of our accumulated losses as disclosed in this document, it is unlikely that we will be eligible to pay dividends out of our profits in the foreseeable future. See "Financial Information — Dividends" for details.

USE OF [REDACTED]

Assuming an [REDACTED] of HK$[REDACTED] per [REDACTED] (being the mid-point of the [REDACTED]), we estimate that we will receive net [REDACTED] of approximately HK$[REDACTED] million from the [REDACTED] after deducting the [REDACTED] and other estimated expenses in connection with the [REDACTED] and assuming that the [REDACTED] is not exercised. In line with our strategies, we intend to use our [REDACTED] from the [REDACTED] for the purposes and in the amounts set forth below:

- Approximately [REDACTED]% of the net [REDACTED], or HK$[REDACTED], is expected to be used for the research, development and commercialization of our Core Products;

- Approximately [REDACTED]% of the net [REDACTED], or HK$[REDACTED], is expected to be used to enhance our overall production capacity; and

- Approximately [REDACTED]% of the net [REDACTED], or HK$[REDACTED], is expected to be used for working capital and general corporate purposes.

See "Future Plans and Use of [REDACTED]."

[REDACTED]

[REDACTED] represent professional fees, [REDACTED], and other fees incurred in connection with the [REDACTED]. We estimate that our [REDACTED] will be approximately HK$[REDACTED], representing [REDACTED]% of the gross [REDACTED] from the [REDACTED] (assuming the [REDACTED] are not exercised and based on the [REDACTED] of HK$[REDACTED]). We estimate the [REDACTED] to consist of (i) approximately HK$[REDACTED] in [REDACTED] related fees, and (ii) approximately HK$[REDACTED] in non-[REDACTED] fees, which consist of (a) fees and expenses of our legal advisors and reporting accountants of approximately HK$[REDACTED], and (b) other fees and expenses of approximately HK$[REDACTED]. During the Track Record Period, [REDACTED] of approximately HK$[REDACTED] was charged to our consolidated income statements and approximately HK$[REDACTED] is expected to be accounted for as a deduction from equity upon the [REDACTED]. After the Track Record Period, approximately HK$[REDACTED] is expected to be charged to our consolidated statements of profit or loss, and approximately HK$[REDACTED] is expected to be accounted for as a deduction from equity upon the [REDACTED]. The [REDACTED] above are the latest practicable estimate for reference only, and the actual amount may differ from this estimate.

RECENT DEVELOPMENT

Our recent developments of our drug candidates since the end of the Track Record Period and up to the Latest Practicable Date include:

- In November 2025, we completed the Phase II clinical trial of WH002; and
- In December 2025, we obtained the IND approval from the NMPA to conduct Phase II clinical trial of WH007.

NO MATERIAL ADVERSE CHANGE

Our Directors have confirmed that, up to the date of this document, there had been no material adverse change in our financial or operational position or prospects since September 30, 2025, being the end date of our latest consolidated statements of financial position, and there has been no event since September 30, 2025 that would materially affect the information shown in the Accountants' Report in Appendix I to this document.